# A Relative Bioavailability Study of Griseofulvin 125 mg/5 mL Suspension Under Fasting Conditions

> **NCT00864071** · PHASE1 · COMPLETED · sponsor: **Actavis Inc.** · enrollment: 50 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Griseofulvin 125 mg/5 mL Suspension, single dose
- **DRUG:** Grifulvin V® 125 mg/5 mL Suspension, single dose

## Key facts

- **NCT ID:** NCT00864071
- **Lead sponsor:** Actavis Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11
- **Primary completion:** 2005-11
- **Final completion:** 2005-11
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2010-08-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00864071

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00864071, "A Relative Bioavailability Study of Griseofulvin 125 mg/5 mL Suspension Under Fasting Conditions". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00864071. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*